
NMTR
Healthcare · Biotechnology & Medical Research · $1.0M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2023
EPS trend, 90 days to now · +29.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 15, 2023 | After the close | -0.78 | -1.02 | -30.8% |
| Mar 28, 2023 | Before the open | -0.76 | -0.92 | -21.1% |
| Nov 8, 2022 | Before the open | -0.82 | -0.72 | +12.2% |
| Aug 15, 2022 | Before the open | -0.83 | -0.80 | +3.6% |
| May 16, 2022 | Before the open | -0.75 | -0.80 | -6.7% |
| Mar 23, 2022 | Before the open | -0.72 | -0.80 | -11.1% |
| Nov 15, 2021 | Before the open | -0.73 | -1.00 | -37.0% |
| Aug 12, 2021 | After the close | -0.60 | -0.60 | 0.0% |
| May 13, 2021 | Before the open | -0.55 | -0.60 | -9.1% |
| Mar 22, 2021 | After the close | -0.82 | -1.00 | -22.0% |
| Nov 9, 2020 | After the close | -1.20 | -1.20 | 0.0% |
| Aug 12, 2020 | After the close | -0.16 | -0.57 | -256.3% |
| May 15, 2020 | After the close | -0.13 |
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a…
| -0.07 |
| +46.2% |
| Mar 20, 2020 | After the close | -0.13 | -0.25 | -92.3% |
| Nov 7, 2019 | After the close | -2.80 | -5.20 | -85.7% |
| Aug 8, 2019 | After the close | -2.60 | -2.64 | -1.5% |
| May 10, 2019 | After the close | -2.40 | -3.20 | -33.3% |
| Mar 18, 2019 | After the close | -0.11 | -0.11 | 0.0% |
| Nov 13, 2018 | After the close | -4.20 | -0.60 | +85.7% |
| Aug 14, 2018 | After the close | -4.20 | -3.20 | +23.8% |
| May 15, 2018 | After the close | — | -0.76 | — |
| Mar 13, 2018 | After the close | — | -2.95 | — |